Inhibikase Therapeutics第一季度每股收益$（0.15）错过$（0.12）估计

Inhibikase Therapeutics (NASDAQ: IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share from the same period last year.